Japanese company Ono Pharmaceutical has adopted Canadian-based Kinaxis Inc.’s AI-infused supply chain orchestration platform to help bring full visibility and transparency across its global supply chain.
Kinaxis Maestro is intended to help drive operational efficiencies for Ono, empowering the company to expand and diversify its portfolio of life-saving drugs. The transformation comes at a time when Ono is preparing for an increase of direct sales in the U.S. and Europe.
“Under the corporate philosophy ‘Dedicated to the Fight against Disease and Pain,’ Ono continues to contribute to and work toward the realization of a sustainable society through the generation of innovative drugs,” said Akira Takada, corporate executive officer, executive director, CMC and production at Ono Pharmaceutical. “Kinaxis will play an important role in bolstering the supply chain efficiency required to ensure a stable delivery of medicines Ono creates across a broad range of therapeutic areas to patients worldwide.”
Ono Pharmaceutical, headquartered in Osaka, Japan, is an R&D-oriented pharmaceutical company committed to creating innovative medicines in specific areas. Ono focuses its research on oncology, immunology, neurology and specialty research with high medical needs as priority areas for discovery and development of innovative medicines. The company has multiple subsidiaries and manufacturing facilities in Japan and overseas and is currently expanding its overseas business with the goal of a becoming a global specialty pharma.
“The need for agility-driven transformation to meet challenges and drive business success is imperative in today’s uncertain world,” said Toshiya Kaneko, president at Kinaxis Japan. “With Kinaxis, Ono will be empowered to plan for any scenario, making them more resilient to whatever comes around the corner and bolstering their mission of delivering life-saving drugs to their patients.”
Leave a Reply